GlassScriptPhysician profile
Ahmed Eddib
NPI 1982277273
$1,109.14
in general payments reported to CMS, 2019-2025
12 companies · $549 in 2025
The $549 reported for 2025 was more than what 80% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $29.12 · 2024: $531 · 2025: $549.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,109.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,109.14 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $218.60 | 2023-2025 | Tezspire, Fasenra, Imfinzi |
| Abiomed | $168.65 | 2024-2025 | Impella |
| Abbvie INC. | $149.88 | 2024 | |
| Stryker Corporation | $147.35 | 2025 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Glaxosmithkline, LLC. | $82.51 | 2024-2025 | Nucala |
| Inspire Medical Systems, INC. | $77.10 | 2025 | Inspire |
| Jazz Pharmaceuticals INC. | $56.68 | 2025 | |
| Grifols USA, LLC | $56.18 | 2024-2025 | Prolastin-C Liquid |
| Amgen INC. | $48.22 | 2025 | Tezspire |
| Genzyme Corporation | $45.44 | 2025 | |
| Harmony Biosciences LLC | $30.30 | 2025 | |
| Merck Sharp & Dohme LLC | $28.23 | 2024 | Winrevair |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ahmed Eddib listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.